新辅助T-DXd治疗高危HER2阳性早期乳腺癌:证据是否支持其成为新标准?
本文针对DB11随机临床试验结果进行评论,该试验似乎支持T-DXd序贯紫杉醇、曲妥珠单抗和帕妥珠单抗作为高危HER2阳性早期乳腺癌的新辅助治疗选择。作者认为试验设计中的主要终点选择、样本量计算、潜在偏倚来源及复发后治疗欠佳等因素限制了结果解读,当前证据尚不足以支持将 upfront 新辅助T-DXd作为标准治疗。
要点
- DB11结果鼓励继续探索T-DXd新辅助策略,但证据尚不支持其作为标准治疗。
- 主要终点选择、样本量计算、潜在偏倚及复发后治疗欠佳影响结果解读。
- 需谨慎看待DB11的定性及定量结果,等待更多证据。
核心结论
- 当前证据不足以支持将 upfront 新辅助T-DXd作为高危HER2阳性早期乳腺癌的标准治疗选择。
研究设计与样本
- 本文为针对DB11随机临床试验的评论文章,未报告原始研究样本量。
主要发现
- DB11试验结果看似支持T-DXd序贯紫杉醇、曲妥珠单抗和帕妥珠单抗作为潜在新辅助选择。
- 作者认为试验设计及实施中的若干因素可能定性和定量影响结果。
关键数值与推荐
- 主要终点选择、样本量计算、潜在偏倚来源及入组患者复发后治疗欠佳是主要关注点。
临床怎么用
- DB11结果鼓励继续探索该创新策略,但不应将 upfront 新辅助T-DXd视为标准治疗。
局限性
- 试验设计及实施中的局限性(主要终点、样本量、偏倚、复发后治疗)实质限制结果可解释性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic landscape for HER2-positive breast cancer (BC) is evolving rapidly with the advent of antibody-drug conjugates such as trastuzumab deruxtecan (T-DXd). Recently, positive results from the Destiny Breast 011 (DB11) randomized clinical trial were reported, seemingly supporting T-DXd followed by paclitaxel, trastuzumab, and pertuzumab as a potential new neoadjuvant treatment option for high-risk, HER2-positive early breast cancer (eBC). However, in our view, several elements of the trial's design and conduct may have affected the results both qualitatively and quantitatively. These concerns include the selection of the primary endpoint, the sample-size calculation, potential source of bias and the suboptimal post-recurrence therapies administered to patients enrolled. Taken together, these limitations substantially constrain the interpretability of the trial's findings. In this commentary, we discuss why, although the DB11 results are encouraging and justify continued exploration of this innovative therapeutic strategy, the current evidence remains insufficient to support upfront neoadjuvant T-DXd as a standard-of-care option for patients with high-risk, HER2-positive eBC.
引用
- Conforti F, Sala I, Pala L, et al. "Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?". Eur J Cancer. 2026. PMID: 42142430. doi:10.1016/j.ejca.2026.116796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。